CN106177176B - A kind of Halth-care composition and its preparation method and application - Google Patents
A kind of Halth-care composition and its preparation method and application Download PDFInfo
- Publication number
- CN106177176B CN106177176B CN201610726947.XA CN201610726947A CN106177176B CN 106177176 B CN106177176 B CN 106177176B CN 201610726947 A CN201610726947 A CN 201610726947A CN 106177176 B CN106177176 B CN 106177176B
- Authority
- CN
- China
- Prior art keywords
- weight
- ginseng
- parts
- preparation
- halth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 241000208340 Araliaceae Species 0.000 claims abstract description 56
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 55
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 55
- 235000008434 ginseng Nutrition 0.000 claims abstract description 55
- 230000036039 immunity Effects 0.000 claims abstract description 31
- 239000009636 Huang Qi Substances 0.000 claims abstract description 21
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 235000019441 ethanol Nutrition 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000000843 powder Substances 0.000 claims description 28
- 239000000284 extract Substances 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 18
- 239000006071 cream Substances 0.000 claims description 17
- 238000000605 extraction Methods 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 230000036541 health Effects 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 13
- 238000007873 sieving Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 244000241838 Lycium barbarum Species 0.000 claims description 2
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000002710 Ilex cornuta Nutrition 0.000 claims 1
- 241001310146 Ilex cornuta Species 0.000 claims 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 claims 1
- 239000000469 ethanolic extract Substances 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 16
- 210000004185 liver Anatomy 0.000 abstract description 16
- 210000003734 kidney Anatomy 0.000 abstract description 14
- 238000005728 strengthening Methods 0.000 abstract description 8
- 235000019640 taste Nutrition 0.000 abstract description 3
- 230000001755 vocal effect Effects 0.000 abstract description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 63
- 238000000034 method Methods 0.000 description 30
- 239000013642 negative control Substances 0.000 description 24
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 20
- 206010016256 fatigue Diseases 0.000 description 20
- 210000000952 spleen Anatomy 0.000 description 20
- 238000012360 testing method Methods 0.000 description 18
- 241001065361 Gynostemma Species 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 230000000242 pagocytic effect Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 241000287828 Gallus gallus Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 206010057249 Phagocytosis Diseases 0.000 description 7
- 210000003024 peritoneal macrophage Anatomy 0.000 description 7
- 230000008782 phagocytosis Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003228 hemolysin Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 108010006464 Hemolysin Proteins Proteins 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 208000026935 allergic disease Diseases 0.000 description 5
- 230000007815 allergy Effects 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000976 ink Substances 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- -1 flavone compound Chemical class 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 208000033065 inborn errors of immunity Diseases 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000019353 potassium silicate Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- YHVQIDWAIRCSOQ-UHFFFAOYSA-N 1-nitrotetrazol-2-ium chloride Chemical compound [Cl-].[O-][N+](=O)N1C=[NH+]N=N1 YHVQIDWAIRCSOQ-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000142975 Cornaceae Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229920003020 cross-linked polyethylene Polymers 0.000 description 1
- 239000004703 cross-linked polyethylene Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- WIPCMBDEWMKHCR-UHFFFAOYSA-N dimethyl sulfate;phenazine Chemical compound COS(=O)(=O)OC.C1=CC=CC2=NC3=CC=CC=C3N=C21 WIPCMBDEWMKHCR-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 229940029988 ginseng preparation Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- GKQWYZBANWAFMQ-UHFFFAOYSA-M lithium;2-hydroxypropanoate Chemical compound [Li+].CC(O)C([O-])=O GKQWYZBANWAFMQ-UHFFFAOYSA-M 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Abstract
The invention discloses a kind of Halth-care composition enhanced human immunity, the composition is made of raw material from the following weight: 450~550 parts by weight of Radix Astragali, 300~400 parts by weight of Fructus Corni, 100~200 parts by weight of 300~400 parts by weight of fructus lycii, 150~250 parts by weight of gynostemma pentaphylla and ginseng.Radix Astragali, Fructus Corni, fructus lycii, gynostemma pentaphylla and the ginseng five tastes share in the composition, yang blood and qi giving young employees remedial-courses in general knowledge and vocational skills, and strengthening the essence green blood is nourishing liver and kidney, have exact effect to strengthen immunity.The invention also discloses the preparation methods of the composition.
Description
Technical field
The present invention relates to a kind of Halth-care compositions and its preparation method and application enhanced human immunity, belong to health care
Product field.
Background technique
The immune function of human body is one of defence line, escorts human health；It is that one kind gets rid of illness ability again, after people's illness
It can promote rehabilitation, this just becomes the disease-resistant basic place of human body salubrity.However, in daily life, making human body there are many factor
There is immunologic derangement in immunity degradation.For example, diet is unreasonable, protein, vitamin, microelement insufficiency of intake；Life
It is irregular, sleep insufficiency；Lack exercise exercise, poor to the adaptability of environment；Stress, it is overworked；Using hormone,
The adverse reaction of antibiotic etc, it is suppressed that immunity；Immunity is temporarily reduced when suffering from acute disease, suffers from chronic diseases Shi Zechang
Phase is in hypoimmunity state etc..If long-time hypoimmunity, human body just will appear the intermediate shape of health and disease
State-sub-health state.And sub-health state is continuous Change and Development, cannot such as be improved in time, it is more likely that disease
Condition conversion.It is to move towards the basic method of health far from inferior health so improving human autoimmune's function.China is relevant
Survey data shows have 60% or more crowd to be in sub-health status, rely solely on drug symptomatic treatment and be difficult to restore
To normal healthy state.
Fatigue is a kind of signal for prompting body to already exceed normal duty.Fatigue is mostly since work, learning tasks are numerous
Weight, caused by rhythm of life is nervous.Fatigue includes two aspect of physiology and psychology.Physiological fatigue is mainly shown as DOMS, whole body
It is tired etc.；And mental fatigue is mainly shown as irritated, absent minded, thought slowness of mood etc..The 1980s mid-term,
Medical field proposes " chronic fatigue syndrome " this concept, it is indicated that fatigue is also a kind of disease.Chronic fatigue syndrome refers to tired
A kind of long-term fatigue and weak state caused by labor, the general malaise that cannot be alleviated and lying up, apathetic, brothers are sour
For a series of syndromes such as soft, memory is not concentrated, working efficiency is low.In recent years, it since fatigue induces sudden illness, leads
Cause existing disease condition to aggravate, in addition threaten life example it is more and more, people for fatigue harm understanding also further
Deeply.Modern medicine is shown experimentally that " fatigue " can not be cured or be eradicated, because it is not disease but one kind is unhealthy
Physical and mental statuse, just take effective intervening measure but if not developing into before " chronic fatigue syndrome " in " fatigue ", and
It makes the life better habit, can effectively relieve fatigue and eliminate the threat of " chronic fatigue syndrome ".
With the quickening of modern society's life rhythm, people will not only bear the multiple of the various aspects such as study, work, life
Pressure, and since environmental pollution is got worse, many people are in " inferior health " state, are mainly shown as under immunity of organisms
Drop, susceptible fatigue etc..Medical research shows that the disease of the mankind 99% is all related with immune system, therefore, to prevention disease
Occur, the physique kept fit, it is crucial for improving immunity, while often in crowd's body immune system under fatigue state
Function can constantly decline, and how mitigating and eliminating fatigue also becomes the major issue for improving immunity.Due to hypoimmunity, easily
Various people's quantity of fatigue state is still being continuously increased, the stronger health care for enhancing human immunity and relieving fatigue of specific aim
The market demand of product is increasing.However, safely, effectively, low cost, enhancing human immunity and delay suitable for long-term use
The health care product of solution fatigue still lacks.
Summary of the invention
In order to solve the above technical problems, can effectively be enhanced human immunity one of the objects of the present invention is to provide a kind of
Halth-care composition；
The second object of the present invention is to provide the preparation method of the Halth-care composition；
The third object of the present invention is to provide the preparation using the Halth-care composition as active constituent；
The fourth object of the present invention is to provide the Halth-care composition in the health care product that preparation enhances human immunity
Purposes.
One of to achieve the above object, it is described the present invention provides a kind of Halth-care composition enhanced human immunity
The raw material of composition includes: Radix Astragali, Fructus Corni, fructus lycii, gynostemma pentaphylla and ginseng.
Wherein, Radix Astragali is the dry root of leguminous mongolian scutellaria.It is sweet in flavor, it is warm-natured.Return lung, the spleen channel have invigorating qi for strengthening superficies
And other effects.It is one of " strengthening the body resistance to consolidate the constitution, tonifying middle-Jiao and Qi " medicine most common in motherland's medicine first recorded in Shennong's Herbal.
Fructus Corni is the drying and ripening pulp of Cornaceae plant Fructus Corni.It is sour, puckery, slightly warm in nature.Return liver and kidney channel.Mountain
The fruit of medicinal cornel has the effect of tonifying the liver and kidney, arresting seminal emission prevent prolapse, is clinically used for treatment dizziness and tinnitus, soreness of waist and knee joint, the diseases such as impotence and seminal emission.
Fructus lycii is the dry mature fruit of Lycium barbarum L. of solanaceae.Sweet in flavor and neutral in nature returns liver, kidney channel.As traditional
Medicine eats two source substances, has the effect of " nourishing liver and kidney, benefiting shrewd head ".Essentials of Matea Medica is recorded: fructus lycii moistens liver and clears liver, nourshing kidney benefit
Gas, production of sperm is supporing yang, qi-restoratives labor, strengthening the bones and muscles, dispelling pathogenic wind for improving eyesight, sharp stool and urine.
Gynostemma pentaphylla is the drying herb of cucurbitaceous plant gynostemma pentaphylla.Bitter, cold in nature, return lung, spleen, kidney channel.It is mended with QI invigorating
The effect of spleen.Mainly containing saponin constituent, amino acids, flavone compound, microelement and polysaccharide etc..
Ginseng is the drying root and rhizome of Araliaceae ginseng.Sweet, slight bitter is put down.Returns spleen, lung, the heart channel of Hang-Shaoyin.Ginseng is for I
One of state's specialty valuable ingredient of traditional Chinese medicine, first appeared in Shennong's Herbal, " tonifying five zang organs, soothe the nerves determine soul, only in ancient medicine books
Palpitation with fear ", is classified as top grade.
Fructus lycii is apt to nourishing liver and kidney essence and blood, cardiopulmonary spleen yin-fluid in the formula of above-mentioned composition, and ginseng is apt to tonifying primordial Qi, has tonifying yin raw
Saliva effect.Two medicines, one tonifying yin, one yang-tonifying, one tonifying primordial Qi of a replenishing vital essence and blood, yang blood and qi giving young employees remedial-courses in general knowledge and vocational skills, the vital organs of the human body are all beneficial, mutually make complementation,
Tonifying Qi training member, strengthening the essence green blood.Fructus Corni sweet acid is gentle, it is main enter liver kidney, can strengthening the essence and supporing yang, be longer than under astringent method burnt, be liver
Deficiency of the kidney void, the key medicine of instability of kidney-QI, it is nourishing liver and kidney to be equipped with ginseng qi-tonifying yin-nourishing；Gynostemma pentaphylla and fructus lycii compatibility QI invigorating tonifying spleen are grown
Nourishing liver and kidney；Ginseng and Radix Astragali compatibility, first warm whole body, inspires qi and blood, excites body vitality；Second tonifying Qi, gas are prosperous then
Blood is raw, and the prosperous then blood of gas can not only build up health, but can righting with eliminating evil.The five tastes share, and strengthen the body resistance to consolidate the constitution, air making-up and spleen enlivening, nourish liver
Kidney achievees the purpose that strengthen immunity and improves fatiguability person quality of life.
Preferably, the parts by weight of the raw material of the composition are as follows: 450~550 parts by weight of Radix Astragali, 300~400 weight of Fructus Corni
Measure part, 100~200 parts by weight of 300~400 parts by weight of fructus lycii, 150~250 parts by weight of gynostemma pentaphylla and ginseng.
As more preferably selecting, the parts by weight of the raw material of the composition are as follows: 480~520 parts by weight of Radix Astragali, Fructus Corni 320
~370 parts by weight, 150~180 parts by weight of 320~370 parts by weight of fructus lycii, 180~220 parts by weight of gynostemma pentaphylla and ginseng.
In some embodiments of the invention, the parts by weight of the raw material of the composition are as follows: 500 parts by weight of Radix Astragali, mountain
350 parts by weight of the fruit of medicinal cornel, 170 parts by weight of 350 parts by weight of fructus lycii, 200 parts by weight of gynostemma pentaphylla and ginseng；
Or 480 parts by weight of Radix Astragali, 370 parts by weight of Fructus Corni, 320 parts by weight of fructus lycii, 180 parts by weight of gynostemma pentaphylla and people
Join 180 parts by weight.
Preferably, the ginseng preparation of Radix Astragali in the composition, Fructus Corni, fructus lycii, gynostemma pentaphylla and 50~90 parts by weight
For extract, surplus ginseng is prepared as fine powder；Further, the ginseng of 70 or 80 parts by weight is preferably prepared as extract,
Surplus ginseng is prepared as fine powder.
Surplus ginseng of the present invention refers to that the remaining ginseng in addition to being used to prepare ginseng extract, surplus people participates in
It is used to prepare the ginseng total amount that the sum of ginseng of extract is formula.Ginseng is rare medicinal herbs in side, is prepared into organic solvent and mentions
Take object that can increase effective component in composition, such as the content of ginsenoside, carbohydrate, amino acids；Meanwhile the mealiness of ginseng compared with
Well, ginseng part beats powder and is used as medicine and can avoid the composition moisture absorption, agglomeration as excipients, advantageous to moulding process, and can reduce big
Measure the use of auxiliary material；Moreover, if ginseng is all prepared as to extractive with organic solvent can lose in ginseng insoluble in organic molten
The component of agent causes to waste, and these components can increase sharply splenocyte, and generate activating phagocytic cells, to enhancing human immunity
The immunity of power, especially enhancing cancer patient has great advantage.
Preferably, Radix Astragali, Fructus lycii P.E are water decoction extract；The extract of Fructus Corni, gynostemma pentaphylla and ginseng is
Extractive with organic solvent；The organic solvent includes all organic solvents that can effectively extract and meet safety requirements, as ethyl alcohol,
Methanol, petroleum ether, ethyl acetate and acetone etc., these solvents may be used alone, can also be used in combination；More preferably it is selected as second
Alcohol.
In one particular embodiment of the present invention, Radix Astragali, Fructus Corni, fructus lycii, gynostemma pentaphylla and ginseng respectively account for 50,35,
35,20,17 parts by weight, and 7 parts by weight of ginseng are used to prepare alcohol extracting thing, surplus ginseng is prepared into fine powder, there is contained be dissolved in
Solvent and the effective component for being dissolved in water reach optimal ratio, so that the ginseng of equivalent is played maximum effectiveness, compared to only
The product of extract or only fine powder, health-care effect optimize.
To achieve the above object two, the present invention also provides the preparation methods of the composition, comprising the following steps:
A, it by Fructus Corni, gynostemma pentaphylla, ginseng organic solvent refluxing extraction suitable time, repeatedly extracts, extracting solution filtration,
Merging filtrate, concentration filtrate recycles organic solution, obtains clear cream, spare；
B, Radix Astragali, fructus lycii are added water to cook, is decocted repeatedly, decocting liquid filtration, merging filtrate, filtrate decompression is concentrated to get clearly
Cream, it is spare；
C, the ginseng of step A surplus is crushed, sieving obtains fine powder, spare；
D, merge A, two kinds of clear creams made from step B, be dried under reduced pressure, gained dry cream is ground into fine powder, sieving, then with step
Fine powder made from C mix to get.
It should be known to those skilled in the art that just needs when step C prepares some preferred compositions of the invention,
Selectable step, these compositions specifically refer to include ginseng fine powder composition.When the composition of preparation does not include people
When joining fine powder, step C is dispensed, and step D also need to only merge the clear cream of step A and B, is dried under reduced pressure, is got dry extract
It is ground into fine powder, is sieved.
Preferably, the ginseng that step A is used to prepare extract is 50~90 parts by weight；More preferably, step A is used to prepare
The ginseng of extract is 70 or 80 parts by weight.
Preferably, the organic solvent of step A can choose ethyl alcohol, ether, petroleum ether, ethyl acetate, acetone, methanol etc.
One of or it is a variety of, be more preferably selected as ethyl alcohol；Organic solvent can choose suitable usage amount, and preferably 5 to 10 times are measured,
6,7 or 8 times of amounts are selected in some embodiments of the invention；Concentration of alcohol preferably 60%~80%；The time of extraction
It is selected according to the solvability of different solvents, preferably 0.5 to 5 hour, is more preferably 1 to 2 hour；The number of extraction with
The yield of medicinal extract is related, also will affect the content of medicinal extract effective component and impurity, preferred extraction time is 1 to 5 time, in this hair
In bright some specific embodiments, extraction time is 1 to 3 time.
Preferably, the dosage of water is Radix Astragali, 6~8 times of fructus lycii amounts when step B is decocted, preferably decocting time be 1~
2 hours, preferably decoction number was 1~3 time.
Preferably, the mesh number of sieving described in step C is 100 mesh, the mesh number of sieving described in step D is 80 mesh.
To achieve the above object three, the present invention also provides using the Halth-care composition as the preparation of active constituent.It can
Routinely preparation process is added conventional formulation auxiliary material and is prepared into common peroral dosage form, wherein the dosage form includes capsule, piece
Agent, granule, pill, powder；Preferably capsule.
Conventional formulation auxiliary material of the present invention, including filler, disintegrating agent, lubricant, suspending agent, adhesive, sweetener,
Corrigent, preservative, matrix etc..Filler includes: starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose
Element, sucrose etc.；Disintegrating agent includes: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, crosslinked polyethylene pyrrolidines
Ketone, low-substituted hydroxypropyl cellulose, croscarmellose sodium etc.；Lubricant include: magnesium stearate, lauryl sodium sulfate,
Talcum powder, silica etc.；Suspending agent includes: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methyl fibre
Tie up element etc.；Adhesive includes: starch slurry, polyvinylpyrrolidone, hydroxypropyl methyl cellulose etc.；Sweetener include: saccharin sodium,
Aspartame, sucrose, honey element, enoxolone etc.；Corrigent includes: sweetener and various essence；Preservative includes: nipalgin
Class, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, the fixed, eucalyptus oil of acetic acid chloroethene etc.；Matrix includes:
PEG6000, PEG4000, insect wax etc..
To achieve the above object four, the present invention also provides the Halth-care compositions enhance human immunity in preparation and
The purposes in health care product relieved fatigue.
The beneficial effects of the present invention are: Radix Astragali, Fructus Corni, fructus lycii, gynostemma pentaphylla and the ginseng five tastes share, yang blood and qi
Giving young employees remedial-courses in general knowledge and vocational skills, strengthening the essence green blood is nourishing liver and kidney, inspires qi and blood, and excitation body vitality is built up health, strengthening vital QI to eliminate pathogenic factors, strengthen immunity
And fatiguability person quality of life is improved, to enhancing human immunity with preferable effect, in particular by preferred parts by weight
The composition effect that component obtains is more prominent；Part ginseng is prepared as extract, surplus ginseng is prepared as fine powder, obtains
Composition with it is easily molded, save auxiliary material, reduce waste and effective component abundance advantage, can reduce it is industrial at
This.
Specific embodiment
Below by way of specific embodiment, above content of the invention is described in further detail.But it should not incite somebody to action
This range for being interpreted as the above-mentioned theme of the present invention is only limitted to example below.All technologies realized based on above content of the present invention
Scheme all belongs to the scope of the present invention.
Embodiment 1
1.1 disintegrating process are investigated
Method: weighing 3 parts of the net medicinal material of ginseng, and each 100g is ground into fine powder after 60 DEG C of low temperature dryings, sieves with 100 mesh sieve,
It weighs, calculates flour extraction, the results are shown in Table 1.
1 pulverizing medicinal materials technique of table investigates result
Test result shows that the average flour extraction that ginseng crushes is 96.42%.
1.2 ethanol extraction process are investigated
(1) determination of test objective and performance assessment criteria
Pass through multifactor orthogonal test, the parameters of preferred alcohol extraction process.With alcohol extracting dry spun and always
Saponin content is as performance assessment criteria, to select optimal technological parameter.
(2) design of orthogonal test
1. factor and horizontal selection and the selection of orthogonal arrage: the cause for influencing alcohol extracting is known as concentration of alcohol (A), ethyl alcohol use
Measure (B), extraction time (C) and extraction time (D), 3 levels of each factor design, factor and water on the basis of this 4 factor
It is flat to be shown in Table 2.For system, comprehensive, the specific technological parameter for investigating alcohol extracting, L is selected9(34) orthogonal manner set
Meter research, L9(34) orthogonal arrage is shown in Table 3.
2 alcohol extracting experimental factor water-glass of table
2. test method and result: Fructus Corni 35g, gynostemma pentaphylla 20g, ginseng 7g are weighed, total 62g, parallel 9 parts, at random
It is 1-9 tested number that sampling, which is compiled,.By orthogonal arrage L9(34) in each tested number require to be tested, combined extract filters, filter
Liquid is for calculating dry spun, measurement total saponin content.
3 alcohol extracting L of table9(34) orthogonal arrage and orthogonal experiments
(remarks: K, total influence of each factor level on index；K, the average influence of each factor level；R (very poor)=kmax-
kmin, represent the primary and secondary sequence of factor)
3. analysis and conclusion: being analyzed according to the data of table 3, alcohol extracting dry spun the results of analysis of variance is shown in Table 4, alcohol extracting
Total saponin content the results of analysis of variance is shown in Table 5.
4 alcohol extracting dry spun the results of analysis of variance of table
(F0.05(2.2)=19.0, F0.01(2.2)=99.0)
5 alcohol extracting total saponin content the results of analysis of variance of table
(F0.05(2.2)=19.0, F0.01(2.2)=99.0)
By above data analysis it is found that when using dry spun as inspection target, A1>A2>A3, B3>B2>B1, C3>C2>C1, D3>
D2>D1, the influence of D factor is maximum, and C, A factor are taken second place, and B factor is minimum.In conjunction with 4 dry spun variance analysis of table, each factor effect master
Secondary is D>C>A>B, and wherein D is because being known as significant difference (P<0.05), A, B, C factor there are no significant difference (P>0.05), because
This alcohol extracting taking technique should be A1B3C3D3。
When using total saponin content as inspection target, A2>A1>A3, B3>B2>B1, C2>C3>C1, D2>D3>D1, the influence of D factor is most
Greatly, A, C factor are taken second place, and B factor is minimum.In conjunction with 5 total saponin content variance analysis of table, each factor effect primary and secondary is D > A > C > B,
Middle D is because being known as significant difference (P<0.05), A, B, C factor there are no significant difference (P>0.05), therefore alcohol extracting taking technique is answered
For A2B3C2D2。
The above analysis, it is contemplated that the purpose of this technique is intended to extract the effective component in medicinal material, while from diminution
Volumes of formulation reduces dose, reduces cost, the factors such as energy saving are set out, therefore alcohol extracting optimised process is preferably
A2B3C2D2., that is, 8 times of 70% alcohol refluxs of amount are added and extract 2 times, extract 1.5 hours every time.1.3 decocting extraction processes are investigated
(1) determination of test objective and performance assessment criteria
Pass through multifactor orthogonal test, the preferably parameters of water extraction process.Dry spun and Thick many candies are mentioned with water
Amount is used as performance assessment criteria, to select optimal technological parameter.
(2) design of orthogonal test
1. factor and horizontal selection and the selection of orthogonal arrage: the principal element for influencing water boiling and extraction has decoction number
(E), amount of water (F) and decocting time (G), on the basis of this factor, 3 levels of each factor design, factor is shown in level
Table 6.In order to more specifically investigate the technological parameter of water extraction, we select L9(34) orthogonal manner is designed research, L9(34)
Orthogonal test table is shown in Table 7.
6 water of table mentions experimental factor water-glass
2. test method and result: weighing Radix Astragali 50g, fructus lycii 35g, amount to 85g, parallel 9 parts, it is 1 that grab sample, which is compiled,
~9 tested numbers.It is tested by tested number requirement each in table 7, decocting liquid filtration, merging filtrate, filtrate is concentrated and is settled to
Certain volume, for following tests (dry spun, Thick many candies assay).
7 water of table mentions L9(34) orthogonal arrage and orthogonal experiments
(remarks: K, total influence of each factor level on index；K, the average influence of each factor level；R (very poor)
=kmax-kmin, represent the primary and secondary sequence of factor)
3. analysis and conclusion: being analyzed according to the data of table 7, water mentions dry spun and Thick many candies content variance analysis knot
Fruit is shown in Table 8.
8 water of table proposes dry spun and Thick many candies content variance analysis
(F0.05(2.2)=19.0, F0.01(2.2)=99.0)
It is intuitively analyzed by the K value and R value of table 7, when using dry spun as inspection target, A2>A3>A1, B3>B1>B2, C3>C2>
C1, and maximum is influenced according to 8 C factor of table, A, B factor are taken second place, and each factor effect primary and secondary is C > A > B, and wherein C is aobvious because being known as
Sex differernce, A, B factor there are no significant difference are write, therefore extraction process by water should be A2B3C3。
When using Thick many candies content as inspection target, A2>A3>A1,B3>B2>B1,C2>C3>C1, and each factor of A, B, C influence according to
Secondary is C > A > B, and wherein C factor tool influences most significant, there is significant difference；A, B factor influences smaller, and there was no significant difference, directly
Seeing analysis optimised process is A2B3C2。
From the interpretation of result of These parameters, the purpose that this technique should be comprehensively considered be intended to extract in medicinal material it is effective at
Divide, the volume of diminution preparation, reduce dose, while from cost is reduced, energy saving and raising production efficiency is set out, determined originally
The decocting part Optimal technique process of technique is A2B3C2, that is, medicinal material is weighed, is added water to cook 2 times, 8 times of amount water are added every time, it is each to decoct
It boils 2 hours.
Composition prepares embodiment
Table 9 is formulated
Embodiment 2
According to the 1st group of formula in table 9.
(1) Fructus Corni, gynostemma pentaphylla, people are participated in into 8 times of 70% alcohol refluxs of amount extraction 2 times, 1.5 hours every time, extracting solution
Filtration, merging filtrate (dregs of a decoction abandoning), filtrate recycling ethanol (- 0.065~-0.075Mpa, 65 DEG C), and be concentrated into relative density and be
The clear cream of 1.30-1.35 (60 DEG C of surveys), it is spare.
(2) Radix Astragali, fructus lycii is taken to add water to cook 2 times, every time plus 8 times of amount water, decoction 2 hours, decocting liquid filter, merging filtrate
(- 0.065~-0.075Mpa, 75 DEG C) is concentrated to relative density as 1.30-1.35's (60 DEG C of surveys) in (dregs of a decoction abandoning), filtrate decompression
Clear cream, it is spare.
(3) merge above two clear cream, be dried under reduced pressure (- 0.085Mpa, 65 DEG C), gained dry cream is ground into fine powder, crosses 80
Mesh obtains composition.
Embodiment 3~5
Composition is prepared by 2 method of embodiment according to the 2nd~4 group of formula of table 9 respectively.
Embodiment 6
Raw material components are shown in Table the 1st group of formula in 9, prepare according to the following steps:
(1) Fructus Corni, gynostemma pentaphylla, ginseng (7g) plus 8 times of 70% alcohol refluxs of amount are extracted 2 times, 1.5 hours every time, is mentioned
Liquid is taken to filter, merging filtrate (dregs of a decoction abandoning), filtrate recycling ethanol (- 0.065~-0.075Mpa, 65 DEG C), and be concentrated into relatively close
Degree is the clear cream of 1.30-1.35 (60 DEG C of surveys), spare.
(2) remainder amount ginseng (10g), dry (60 DEG C) crush afterwards, fine powder are sieved with 100 mesh sieve to obtain, with 5kGy dosage60COSpoke
It is spare according to sterilizing.
(3) Radix Astragali, fructus lycii is taken to add water to cook 2 times, every time plus 8 times of amount water, decoction 2 hours, decocting liquid filter, merging filtrate
(- 0.065~-0.075Mpa, 75 DEG C) is concentrated to relative density as 1.30-1.35's (60 DEG C of surveys) in (dregs of a decoction abandoning), filtrate decompression
Clear cream, it is spare.
(4) two kinds of clear creams for merging above-mentioned steps (1) and (3), are dried under reduced pressure (- 0.085Mpa, 65 DEG C), gained dried cream powder
It is broken into fine powder, crosses 80 meshes, is mixed with the ginseng fine powder of step (2), obtains composition.
Embodiment 7
Raw material components are shown in Table the 1st group of formula in 9, and 12g ginseng prepares extract, and surplus ginseng is used to prepare fine powder, presses
6 method of embodiment prepares composition.
Embodiment 8
According to the 2nd group of formula of table 9,8g ginseng is extracted for ethyl alcohol, and surplus ginseng is used to prepare fine powder, by embodiment 6
Method prepares composition.
Embodiment 9
According to the 3rd group of formula of table 9,5g ginseng is extracted for ethyl alcohol, and surplus ginseng is used to prepare fine powder, by embodiment 6
Method prepares composition.
Embodiment 10
According to the 4th group of formula of table 9,9g ginseng is extracted for ethyl alcohol, and surplus ginseng is used to prepare fine powder, by embodiment 6
Method prepares composition.
Formulation preparation example
Embodiment 11
By 85% ethyl alcohol softwood of the composition of embodiment 2,16 meshes are pelletized, 60 DEG C or less dryings, 14 mesh sieves,
It is packed into No. 0 capsule, is polished, is examined, is packed to get health product capsule agent, every about 0.34g containing composition.
Embodiment 12-18
The composition of Example 3~10 is prepared with the method for being same as embodiment 11.
19 strengthen immunity function test of embodiment
1.1 samples: the sample 1 that the lot number according to the preparation of the method for embodiment 6 and embodiment 11 is 20070902 carries out poison
Pharmacologic test carries out function assessment test according to the sample 2 of the method for embodiment 2,7 and embodiment 11 preparation and sample 3.Sample is set
Shady and cool dry and comfortable ventilation saves.2 times a day for everyone (adult), 3 tablets each time, adult weight is based on 60kg for population clothes recommendation dosage
It calculates, converting into dosage is 34mg/kg.Capsule 's content is taken to be tested.
1.2 experimental animals and grouping: cleaning grade health male Kunming strain mice, weight is 18-22 grams, by Guangxi medical courses in general
The breeding of University Hospital Experimental Animal Center, Quality of Experimental Animals quality certification number: N0.0000902.10 mouse of each dosage group.
Immune I group, carries out the mouse spleen lymphocyte transformation experiment of ConA induction；Immune II group, carries out delayed hair allergy experiment；
Immune III group carries out dirty/body ratio measurement, serum hemolysin measurement and the measurement of antibody-producting cell number；It is IV~VI group immune,
Carbonic clearance experiment, peritoneal macrophage phagocytosis chicken red blood cell experiment and NK cytoactive detection are carried out respectively.
1.3 experimental situation conditions: experimental animal room temperature: 22-25 DEG C, relative humidity: 55-70%.Experimental animal makes
With credit number: the osmanthus SYXK 2007-0003.
The selection of 1.4 dosage gives mode with tested material: being taken according to population and recommends dosage, if sample low, middle and high dose groups point
Not Wei 170,340,680mg/kg (be respectively equivalent to human body and recommend 5,10,20 times of dosage), if a negative control group, every group
10 animals.Weigh sample 850,1700,3400g respectively, respectively plus distilled water is to 100mL, mix, be made into 8.5,17.0,
The suspension of 34.0mg/mL concentration gives corresponding dosage group animal stomach-filling by the volume of 0.2mL/10g, and negative control group gives
Isometric distilled water, daily stomach-filling is primary, and continuous gavage 30 days.
1.5 key instruments and reagent: animal platform balance, electronic analytical balance, centrifuge, clean bench, carbon dioxide training
Support case, constant water bath box, microscope, semi-automatic biochemical analyzer, microplate reader etc..
Sterile surgical instrument, micro syringe, cell counter, the flat tissue culture plate in 24 holes and 96 holes, 96 holes are U-shaped thin
Born of the same parents' culture plate, glass dish, gauze, glass slide, test tube, 200 mesh screens, timer hemoglobin pipet etc..
Sheep red blood cell (SRBC) (SRBC), physiological saline, Hank's liquid (pH 7.2-7.4), RPMI1640 culture solution, small ox blood
Clearly, penicillin, streptomysin, ConA, 1% glacial acetic acid, the HCL solution of 1mol/L, isopropanol, MTT, DNFB, PBS buffer solution
(pH7.2-7.4), complement (guinea pig serum), SA buffer, agarose, YAC-1 cell, lithium lactate, nitro tetrazolium chloride,
Phenazine Dimethyl Sulfate, oxidized coenzyme I, the Tris-HCL buffer of 0.2mol/L, 1% NP40, india ink,
Sodium carbonate, chicken red blood cell, methanol, Gimsa dye liquor of 0.l% etc..
1.6 experimental method
1.6.1 internal organs/weight ratio measurement: putting to death mouse after weighing, thymus gland and spleen is taken out, on electronic analytical balance
Weighing calculates dirty/body ratio.
1.6.2ConA the mouse spleen lymphocyte transformation experiment (mtt assay) induced:
It is sterile to take spleen, it is placed in the plate for filling appropriate sterile Hank's liquid, cell suspension is made, through 200 mesh screen mistakes
Filter.It is washed 2 times with Hank's liquid, is centrifuged l0min (1000r/min) every time.Then cell is suspended in 1mL complete culture solution,
Living cell counting number is 3*10 with RPMI1640 culture solution adjustment cell concentration6A/mL..It is divided to two holes to be added cell suspension again
In 24 well culture plates, every hole 1mL, 75uL ConA liquid (being equivalent to 7.5uL/mL) is added in a hole wherein, another hole conduct pair
According to setting 5%CO2, 72h is cultivated in 37 DEG C of carbon dioxide incubators.4h gently sucks supernatant 0.7mL before culture terminates, and is added
0.7mL is free of the RPMI1640 culture solution of calf serum, while the hole MTT (5mg/mL) 50uL/ is added, and continues to cultivate 4h.Culture
After, 1mL acid isopropyl alcohol is added in every hole, and piping and druming mixes, is completely dissolved purple crystal, is then dispensed into 96 well culture plates
In, 3 parallel holes are made in each hole, with microplate reader, measure OD value with 570nm wavelength.The proliferative capacity of lymphocyte, which is used, to be added
The OD value in the hole ConA subtracts the OD value expression that the hole ConA is not added.
1.6.3 the mouse DTH of dinitrofluorobenzene induction tests (ear swelling method):
Experiment terminates first 5 days for mouse part skin depilation about 3cm × 3cm range, is uniformly smeared with 50uL DNFB solution
10uL DNFB is uniformly applied to mouse right ear two sides after 5 days and attacked by sensitization, and cervical dislocation puts to death mouse after 24 hours,
Left and right auricular concha is cut, auricle, the weighing of 8mm diameter are removed with punch, the degree of DTH is indicated with the difference of left and right ear weight.
1.6.4 antibody-producting cell detection (Jerne improves slide method)
The sheep blood for taking de- fiber is centrifuged l0min (2000r/min) every time, is used physiological saline with brine 3 times
Hematocrit SRBC is made into the cell suspension of 2% (v/v), 0.2mL is injected intraperitoneally in every mouse.5 days mouse are put to death after will be immune, are taken
Spleen is gently ground, and cell suspension, 200 mesh net filtrations is made with Hank's liquid, washing, centrifugation 2 times finally suspend cell
In 5mL Hank's liquid.After surface layer culture medium (lg agarose adds distilled water to l00mL) is dissolved by heating, 45~50 DEG C of water are put
Bath heat preservation, mixes with Hank ' the s liquid of equivalent pH7.2-74,2 times of concentration, dispenses small test tube, every pipe 0.5mL, then add into pipe
10%SRBC50uL (v/v), the 25uL splenocyte suspension prepared with SA liquid, are poured into brush agarose thin layer after mixing rapidly
On slide, after to be solidified, flat buckle of slide is placed in glass frame, is put into carbon dioxide incubator and is incubated for 1.5h, buffered with SA
The diluted complement of liquid (1:8) is added in glass frame groove, continues to be incubated for 1.5h, counts hemolysis plaque number.It is thin with plaque number/full spleen
Born of the same parents indicate antibody-producting cell number.
1.6.5 the measurement (Hemagglutination Method) of serum hemolysin
The sheep blood for taking de- fiber is centrifuged l0min (2000r/min) every time, is used physiological saline with brine 3 times
Hematocrit SRBC is made into the cell suspension of 2% (v/v), 0.2mL is injected intraperitoneally in every mouse.After 5 days immune, the eyeball of mouse is extractd,
Take blood in centrifuge tube, placement about 1h, 2000r/min are centrifuged l0min, and serum is collected in separation.With physiological saline by serum multiple proportions
Dilution, the serum of different dilutions is respectively placed in Microhemagglutination plate, every hole l00uL adds 100u L 0.5% (V, v)
SRBC suspension be uniformly packed into wet square position and cover, in 37 DEG C of incubation 3h, observe hemagglutination degree.As the following formula
Calculating antibody product:
Antibody product=(S1+2S2+3S3 ...~nSn.)
1,2,3 ... n are the index of two-fold dilution in formula, and s is the rank of agglutination degree.
1.6.6 mouse carbonic clearance is tested
Through tail vein to 4 times of mouse injection normal saline dilution of india ink, every l0g weight injects 0.lmL, prepared Chinese ink
Timing immediately after injection, the 2nd, l0min after injecting prepared Chinese ink take blood 20u L from intraocular corner of the eyes veniplex respectively, are added to 2mL
In 0.l%Na2CO3 solution, shake up.Make blank control with Na2CO3 solution, it is close with 600nm wavelength survey light with semi-automatic biochemical analyzer
Angle value (OD).Mouse is put to death, liver, spleen are taken, is weighed.Phagocytic index a is calculated as follows.
A=K1/3K=(lgOD in × weight/(liver weight+spleen weight) formula1-lgOD2)/(t2-t1)
1.6.7 Turnover of Mouse Peritoneal Macrophages phagocytosis chicken red blood cells experiment (half intracorporal method)
The hematocrit chicken erythrocyte suspension of 20% (v/v, with normal saline), every mouse 1mL, interval are injected to mouse peritoneal
10min, cervical dislocation put to death mouse, and abdominal skin is cut off in center, and Intraperitoneal injection 2mL physiological saline rotates mouse plate 1min, are sucked out
Abdominal cavity washing lotion 1mL, mean droplet are put into the enamel box for being lined with wet gauze on 2 glass slides, are set 37 DEG C of incubators and are incubated 30min.
Piece is incubated, takes out after slide rinses in physiological saline and dries, with methanol: acetone (1:1) solution is fixed, 4% (v/v) Giemsa-
Phosphate buffer dyes, then is rinsed, dried with distilled water.100 macrophages of every counting, are calculated as follows phagocytosis under oil mirror
Rate and phagocytic index.
Phagocytic rate (%)=phagocytosis chicken red blood cell number of macrophages/counting number of macrophages × 100
The chicken red blood cell sum for phagocytic index=swallowed, the number of macrophages of counting
1.7 experimental datas statistics: variance analysis statistical disposition is carried out using SPSS statistical software.
1.8 result judgements: cellular immune function, humoral immune function, the aspect of monocytes/macrophages function three any two
Aspect result is positive, can determine that the given the test agent has strengthen immunity function.
2. result
Influence of 2.1 samples 1 to mouse weight
10 sample of table, 1 strengthen immunity function test mouse weight
As seen from the above table, mouse during initial stage, the mouse weight of mid-term and each dosage group of latter stage sample 1 and experiment is tested
Body weight increase is compared with negative control group, and no significant difference (P > 0.05), the surface sample is to the body weight increase of mouse without bright
Development is rung.
2.2 samples 1 are to the influence of mouse immune organ internal organs/weight ratio
Immune organ internal organs/weight ratio of 11 sample of table, 1 strengthen immunity function test mouse
As seen from the above table, the sample of orally administration mouse various dose 1 30 days, the thymus gland/weight and spleen/body of mouse
Compared with negative control group, difference that there are no significant (P > 0.05) shows the sample 1 to the immune organ weight of mouse to weight ratio
It has no significant effect.
Influence of 2.3 samples to the cellular immunity of mouse
2.3.1 influence of the sample to the ConA mouse spleen lymphocyte conversion capability induced
12 sample of table is to mouse spleen lymphocyte transformation experiment result
Note: * is compared with negative control group, P < 0.05；* is compared with negative control group, P < 0.01
As can be seen from the above table, 3 samples 30 days of orally administration mouse various dose, the leaching of 3 each dosage groups of sample
Bar cell transformation capacity is above negative control group, and in addition in sample 3, other than low dose group difference all have conspicuousness (P <
0.05), show that the lymphopoiesis, the conversion capability that have the function of promoting mouse, the especially each dosage group difference of sample 1 have
There is very significant.
2.3.2 influence of the sample to mouse delayed allergy (DTH)
13 sample of table is to mouse delayed allergy (DTH) experimental result
Note: * is compared with negative control group, P < 0.05；* is compared with negative control group, P < 0.01
As seen from the above table, 3 samples 30 days of orally administration mouse various dose, the left and right auricle weight difference of each dosage group
Value is above negative control group, and wherein the height of sample 1,2,3, middle dose group and negative control group comparing difference have conspicuousness (P
< 0.05), and 1 high dose group difference highly significant (P < 0.01) of sample, show that sample 1,2 and 3 has the delayed for promoting mouse
The effect of allergy.
Influence of 2.4 samples to the humoral immunity of mouse
2.4.1 influence of the sample to the antibody-producting cell number of mouse
Antibody-producting cell detection experimental result of 14 sample of table to mouse
Note: * is compared with negative control group, P < 0.05；* is compared with negative control group, P < 0.01
From upper table as it can be seen that 3 samples 30 days of orally administration mouse various dose, the antibody-producting cell number of each dosage group
It is apparently higher than negative control group, and each dosage group and negative control group comparing difference all have conspicuousness (P < 0.05), wherein sample
Product 1,2 each equal highly significants of dosage group difference (P < 0.01), 3 samples all have the antibody-producting cell proliferation for promoting mouse
Effect.
2.4.2 influence of the sample to mice serum hemolysin
15 mouse hemolysin test result of table
Note: * is compared with negative control group, P < 0.05；* is compared with negative control group, P < 0.01
From upper table as it can be seen that 3 samples 30 days of orally administration mouse various dose, the antibody product of each dosage group is above
Negative control group, and each dosage group and negative control group comparing difference all have conspicuousness (P < 0.05), show that 3 samples have
Improve the effect of the serum hemolysin of mouse.
Influence of 2.5 samples to the monocytes/macrophages phagocytic function of mouse
2.5.1 influence of the sample to the monocytes/macrophages carbonic clearance of mouse
16 sample of table is to mouse monokaryon-macrophage carbonic clearance experimental result
Note: * is compared with negative control group, P < 0.05；* is compared with negative control group, P < 0.01
From upper table as it can be seen that 3 samples 30 days of orally administration mouse various dose, the phagocytic index of each dosage group is above
Feminine gender control group, but difference has conspicuousness (P < 0.05) to the middle and high dosage group of only sample 1,2 compared with the control group, table
Bright sample 1,2 has the function of promoting the monocytes/macrophages carbonic clearance function of mouse.
2.5.2 influence of the sample to Turnover of Mouse Peritoneal Macrophages phagocytosis chicken red blood cell ability
17 sample of table swallows chicken red blood cell experiment results to Turnover of Mouse Peritoneal Macrophages
Note: * is compared with negative control group, P < 0.05；* is compared with negative control group, P < 0.01
From upper table as it can be seen that 3 samples 30 days of orally administration mouse various dose, the only peritoneal macrophage pair of sample 1
The phagocytic rate and phagocytic index of chicken red blood cell are significantly higher than negative control group, and the phagocytic rate of each dosage group and phagocytic index and yin
Property control group comparing difference have very significant (P < 0.01), show sample 1 to the phagocytosis function of the peritoneal macrophage of mouse
There can be apparent facilitation.
3. brief summary
Orally administration mouse 170,340,680mg/kg (are equivalent to human body and recommend 5,10,20 times of dosage) 3 samples of dosage
Product 30 days, spleen lymphocyte proliferation, the transformation of mouse can be promoted, the antibody-producting cell of mouse is promoted to be proliferated, improved small
The serum hemolysin of mouse, promotes the delayed allergy of mouse, and sample 1 promotes the monocytes/macrophages carbon of mouse wide
Please function and Peritoneal Macrophage Phagocytosis, to the body weight increase of mouse, thymus gland/weight ratio, spleen/weight ratio without bright
Development is rung, and 3 samples all have the function of preferable strengthen immunity, and especially 3 effect of sample is the most significant.
Claims (8)
1. a kind of Halth-care composition enhanced human immunity, the composition are made of raw material from the following weight: Radix Astragali
500 parts by weight, 350 parts by weight of Fructus Corni, 170 parts by weight of 350 parts by weight of fructus lycii, 200 parts by weight of gynostemma pentaphylla and ginseng, by institute
The ginseng for stating Fructus Corni, gynostemma pentaphylla and 70 parts by weight is prepared as ethanol extract, and surplus ginseng is prepared as fine powder, by Radix Astragali, Chinese holly
Matrimony vine is prepared as water decoction extract.
2. a kind of preparation method of the Halth-care composition described in claim 1 enhanced human immunity, comprising the following steps:
A, Fructus Corni, gynostemma pentaphylla, ginseng alcohol reflux are extracted into suitable time, extracting solution filtration, merging filtrate is concentrated under reduced pressure
Filtrate recycles organic solution, obtains clear cream, spare；
B, Radix Astragali, fructus lycii are added water to cook, decocting liquid filtration, merging filtrate, filtrate decompression is concentrated to get clear cream, spare；
C: the ginseng of step A surplus is crushed, and sieving obtains fine powder, spare；
D, merge A, two kinds of clear creams made from step B, be dried under reduced pressure, gained dry cream is ground into fine powder, sieving, then with step C system
Fine powder mix to get.
3. the preparation method of the Halth-care composition enhanced human immunity as claimed in claim 2, it is characterised in that:
Ethanol consumption described in step A is 5~10 times of amounts, and concentration of alcohol is 60%~80%；The extraction time is 1~5 time；
It is added water to cook described in step B, the dosage of water is 6~8 times of amounts, and decocting time is 1~2 hour, and decocting number is 1~3 time；
Sieving described in step C is 100 meshes；
Sieving described in step D is 80 meshes.
4. the preparation method of the Halth-care composition enhanced human immunity as claimed in claim 3, which is characterized in that described
The dosage of ethyl alcohol is 6~8 times of amounts.
5. the preparation method of the Halth-care composition enhanced human immunity as claimed in claim 3, which is characterized in that described
Extraction time is 1~3 time.
6. the preparation that a kind of active constituent is Halth-care composition described in claim 1, which is characterized in that the preparation is glue
Wafer, tablet, granule, pill, powder.
7. preparation as claimed in claim 6, which is characterized in that the preparation is capsule.
8. purposes of the composition described in claim 1 in the health care product that preparation enhances human immunity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610726947.XA CN106177176B (en) | 2016-08-25 | 2016-08-25 | A kind of Halth-care composition and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610726947.XA CN106177176B (en) | 2016-08-25 | 2016-08-25 | A kind of Halth-care composition and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106177176A CN106177176A (en) | 2016-12-07 |
| CN106177176B true CN106177176B (en) | 2019-11-05 |
Family
ID=57523768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610726947.XA Active CN106177176B (en) | 2016-08-25 | 2016-08-25 | A kind of Halth-care composition and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106177176B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108392543A (en) * | 2018-05-08 | 2018-08-14 | 东莞市亚洲制药有限公司 | A kind of health composition and its preparation method and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940733A (en) * | 2012-09-03 | 2013-02-27 | 吉林一正药业集团有限公司 | Composition for relieving physical fatigue and preparation method and application thereof |
-
2016
- 2016-08-25 CN CN201610726947.XA patent/CN106177176B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940733A (en) * | 2012-09-03 | 2013-02-27 | 吉林一正药业集团有限公司 | Composition for relieving physical fatigue and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 保健食品批文转让目录;mamenghua123ma;《https://wenku.baidu.com/view/1f4ddc573clec5da50e2704c.html》;20110220;第2页A37行 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106177176A (en) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104435775B (en) | A kind of Traditional Chinese medicinal health-care wine and preparation method thereof | |
| CN101708048B (en) | Health-care food and preparation method thereof | |
| CN106176918A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Radix Puerariae | |
| CN103041264B (en) | Kudzuvine root brain-boosting and intelligence-boosting oral solution with function of preventing vascular dementia and preparation method thereof | |
| CN104027529A (en) | Traditional Chinese medicine composition for regulating blood lipids, blood pressure and blood glucose and preparation method thereof | |
| CN103494197A (en) | Health-care food with functions of enhancing immunity and assisting to reduce blood sugar and preparation method of food | |
| CN104305205B (en) | A kind of Semen Cuscutae oral liquid improving immunity and preparation method thereof | |
| CN102240318B (en) | Preparation method and analysis method of traditional Chinese medicine for tonifying qi and increasing breast milk | |
| CN101658597A (en) | Health care step-down tea and preparation method thereof | |
| CN103690784B (en) | The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN101032599B (en) | Healthy solution for conditioning skin and losing weight | |
| CN101168712B (en) | Health preserving wine | |
| CN104352552A (en) | Food, health care product or medicine composition | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN102754833B (en) | Healthcare product with function of enhancing immunity and preparation method thereof | |
| CN106177176B (en) | A kind of Halth-care composition and its preparation method and application | |
| CN107912773A (en) | A kind of preparation for being used to alleviate physical fatigue | |
| CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
| CN107156830A (en) | A kind of composition of strengthen immunity, its preparation method and application | |
| CN104544084B (en) | A kind of health food for diabetics | |
| CN101129638A (en) | Health care medicinal liquor | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| CN102266428B (en) | Anti-ageing Chinese medicinal composition and preparation method and application thereof | |
| CN105815786A (en) | Tablets prepared from honeysuckle flowers, wild chrysanthemum flowers and rhizoma polygonati and preparation method of tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |